Author

P. Chandrani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:whole-exome sequencing· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Alfonso· 1 shared A. Choughule· 1 shared A. Dutt· 1 shared A. Halpern· 1 shared A. Ingle· 1 shared A. Joshi· 1 shared A. Marghoob· 1 shared A. Rossi· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Alfonso

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cellular-level phenotyping of tumor-immune microenvironment (TiME) in patients in vivo reveals distinct inflammation and endothelial anergy signatures

A. Sahu, T. Tembo, K. Kose, A. Santella, A. Alfonso, M. Li, M. Cordova, M. Gill, C. Fox, S. Gonzalez, A. W. Wang, N. R. Kurtansky, P. Chandrani, P. Kumar, S. Yin, , M. Rajadhyaksha

The paper uses in vivo cellular-level imaging to phenotype tumor-immune microenvironments, identifying distinct inflammation and endothelial anergy signatures linked to immunotherapy response.

bioRxiv · Jun 10, 2021Cancer Biology

Merkel cell polyomavirus in Merkel cell carcinoma: Integration sites and involvement of the KMT2D tumor suppressor gene

R. Arora, J. E. Choi, P. W. Harms, P. Chandrani

The paper identifies MCV integration sites in Merkel cell carcinoma using whole exome sequencing and finds no highly recurrent sites, with chromosome 5 most frequent and integration enriched near oncogenic transcription factor binding sites.

bioRxiv · Aug 3, 2020Cancer Biology

ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer

P. Iyer, S. V. Shrikhande, M. Ranjan, A. Joshi, R. Prasad, N. Gardi, R. Thorat, S. Salunkhe, B. Dharavath, B. Sahoo, P. Chandrani, H. Kore, B. Mohanty, V. Chaudhari, A. Choughule, , A. Dutt

This study identifies ERBB2 and KRAS mutations in early-stage gallbladder cancer and shows their impact on response to EGFR inhibitors.

bioRxiv · Mar 28, 2018Cancer Biology